Details for Patent: 7,531,530
✉ Email this page to a colleague
Which drugs does patent 7,531,530 protect, and when does it expire?
Patent 7,531,530 protects RUBRACA and is included in one NDA.
This patent has fifty-nine patent family members in twenty-four countries.
Summary for Patent: 7,531,530
| Title: | Therapeutic compounds |
| Abstract: | The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments. |
| Inventor(s): | Helleday; Thomas (Stockholm, SE), Curtin; Nicola (Tyne and Wear, GB) |
| Assignee: | Cancer Research Technology Limited (London, GB) Pfizer (New York, NY) |
| Application Number: | 10/565,308 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,531,530
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zr Pharma | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION | ⤷ Try a Trial | ||||
| Zr Pharma | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION | ⤷ Try a Trial | ||||
| Zr Pharma | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,531,530
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0317466.1 | Jul 25, 2003 |
| United Kingdom | 0408524.7 | Apr 16, 2004 |
| PCT Information | |||
| PCT Filed | July 23, 2004 | PCT Application Number: | PCT/GB2004/003183 |
| PCT Publication Date: | February 10, 2005 | PCT Publication Number: | WO2005/012305 |
International Family Members for US Patent 7,531,530
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 454893 | ⤷ Try a Trial | |||
| Austria | 516353 | ⤷ Try a Trial | |||
| Australia | 2004261462 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
